Proscia Funding, Investors & Competitors

Proscia has raised $130M across 7 funding rounds, most recently a $50M Series D in March 2025.

Last Proscia funding round

$50M

Series D · Mar 2025

Cumulative funding Proscia raised

$130M

across 7 funding rounds

Key investors in Proscia

  • Robin Hood Ventures
  • Emerald Development Managers
  • Razor's Edge Ventures
  • Flybridge
  • Scale Venture Partners
  • Fusion Fund
  • Hitachi Ventures
  • Triangle Peak Partners

Proscia Overview

About Proscia

Proscia is a Philadelphia-based digital pathology company providing the Concentriq platform for labs and pharma. The AI-powered system scans slides, detects biomarkers, and supports clinical trials with image management for over 20 million slides processed. Partnerships with Roche and Pfizer accelerate diagnostics in oncology and rare diseases.


Founded

2014

HQ

United StatesPhiladelphia, PA

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Proscia Funding History

Proscia has raised a total of $130M across 7 funding rounds.

Proscia's first fundraising round was a $2M seed round in July 2016. The most recent completed round was a $50M Series D in March 2025.

Proscia funding rounds

Proscia funding rounds
DateStageInvestorsRaisedDeal Summary
Mar 2025Series DAlpha Intelligence Capital (lead); Insight Partners (lead); Triangle Peak Partners (lead); GPG Healthcare; Avenue Capital Group; Interwoven Ventures; Razor's Edge Ventures; Fusion Fund; Emerald Development Managers$50MProscia, a Philadelphia-based software company, develops the Concentriq platform to lead pathology's transition to digital and AI, powering precision medicine from drug discovery to diagnostics. On March 19, 2025, it raised $50M in funding led by Insight Partners, Alpha Intelligence Capital (AI Capital Partners), and Triangle Peak Partners, with participation from Avenue Venture Opportunities Fund, Emerald Development Managers, GPG Healthcare, Fusion Fund, Interwoven Ventures, and Razor’s Edge Ventures, bringing total funding to $130M. The capital supports commercial expansion, including OEM partnerships with Agilent Technologies and Siemens Healthineers, and AI enhancements to Concentriq. Proscia serves 16 of the top 20 pharmaceutical companies and anticipates 22,000+ daily patient diagnoses on its platform following record 2024 growth. The funding addresses challenges like rising cancer cases and pathologist shortages by accelerating targeted therapies, diagnosis, and patient-treatment matching. Concentriq underpins the precision medicine value chain, connecting life sciences and labs. By July 2025, Proscia reported 400% year-over-year growth to 32,000 daily diagnoses, with its diagnostic network generating high-margin revenue through real-world data licensing (12M+ slides across 2M patients), AI testbeds for pharma, and precision services like biomarker discovery. Earlier, Proscia raised $37M in a Series C (date unspecified, total funding then $72M) from Highline Capital Management, Triangle Peak Partners, Alpha Intelligence Capital, and others to advance computational pathology, expand Concentriq and DermAI, and grow headcount from ~100. The company integrates with 100+ LIS systems like Epic Beaker and offers extensive AI applications, positioning it as a leader in digital pathology amid partnerships and awards like the 2025 MedTech Breakthrough.
Jan 2024Series CTriangle Peak Partners (lead); Scale Venture Partners; Flybridge; Hitachi Ventures; Razor's Edge Ventures; Fusion Fund; ROBO Global; Highline Capital Management; Robin Hood Ventures; Alpha Intelligence Capital; Emerald Development Managers$9M-
Jun 2022Series CScale Venture Partners; Triangle Peak Partners; Hitachi Ventures; Razor's Edge Ventures; ROBO Global; Highline Capital Management; Robin Hood Ventures; Alpha Intelligence Capital; Emerald Development Managers$37MProscia is a Philadelphia-based software company providing digital and computational pathology solutions through its Concentriq platform, enabling AI applications to advance precision medicine, cancer diagnosis, and research. The company raised $37 million in its Series C funding round announced on June 14, 2022, with participation from new investors Highline Capital Management, Triangle Peak Partners, and Alpha Intelligence Capital, alongside existing backers Scale Venture Partners, Hitachi Ventures, ROBO Global, Emerald Development Managers, and Razor’s Edge Ventures. This brought Proscia’s total funding to $72 million following prior rounds including a $23 million Series B in December 2020 led by Scale Venture Partners. The Series C proceeds were allocated to accelerate adoption of computational pathology by scaling commercial operations, including expansion of sales, marketing, and support teams, and growing distribution partnerships such as its OEM agreement with Siemens Healthineers. Proscia aimed to strengthen its regulatory strategy after achieving CE IVDR certification and broaden its AI portfolio, building on successes like DermAI for melanoma detection and process automation tools like Automated QC. The platform supports a wide variety of AI applications from Proscia and third parties, positioning the company as a leader in transforming the 150-year-old pathology standard of care. Investor Jacob Doft of Highline Capital Management highlighted Proscia’s role in accelerating precision medicine through digital pathology data. Subsequent developments include a $50 million funding round in March 2025 led by Insight Partners, bringing total funding to $130 million amid record growth, with 16 of the top 20 pharmaceutical companies as users and over 22,000 daily patient diagnoses on Concentriq.
Nov 2020Series BScale Venture Partners (lead); Flybridge; Hitachi Ventures; Robin Hood Ventures$23MProscia, founded in 2014, is a Philadelphia-based provider of digital and computational pathology solutions that aims to modernize the 150-year-old analog standard of cancer diagnosis. The company's Concentriq platform combines cloud-based digital pathology software with artificial intelligence applications to enhance accuracy and efficiency in analyzing tissue slides for diseases such as cancer. In December 2020, Proscia closed a $23 million Series B funding round led by Scale Venture Partners with participation from Hitachi Ventures (the corporate venture capital arm of Hitachi, Ltd.), bringing total cumulative funding to $35 million including its $8.3 million Series A. The company had previously raised capital from Flybridge Capital Partners, Emerald Development Managers, Fusion Fund, Razor's Edge Ventures, and RobinHood Ventures. In 2020, the company experienced approximately 11-fold year-over-year revenue growth. The Series B proceeds were allocated to accelerate global commercial expansion, including ramping up sales, marketing, and support teams; expanding its AI application portfolio beyond its initial DermAI offering; and advancing its regulatory strategy to secure FDA clearance, building on existing CE Mark and MDSAP certifications. The round recognized Proscia's position in a multi-billion-dollar market opportunity as pathology undergoes a fundamental digital transformation, with the company having secured partnerships including a notable OEM agreement with Siemens Healthineers announced by the time of its subsequent Series C in June 2022.
Sep 2018Series AFlybridge (lead); SoGal Ventures (lead); Razor's Edge Ventures; Fusion Fund; Robin Hood Ventures; Emerald Development Managers$8MProscia is a Philadelphia-based startup that develops a digital pathology platform to aid in cancer diagnosis through technology. The company raised $8.3 million in a Series A round on September 26, 2018, led by Flybridge Capital Partners, with participation from Fusion Fund, Emerald Development Managers, Razor’s Edge Ventures, and Robin Hood Ventures. Previously, Proscia secured $1 million in a 2016 seed round led by Emerald Development Managers, with Robin Hood Ventures, A-Level Capital, and TCP Venture Capital. Proscia's clients include Thomas Jefferson University Hospitals, Henry Ford Health System, and Johns Hopkins Department of Pathology. The Series A funding supports expansion of its digital pathology software, development of AI-enabled workflows targeting specific cancers, and growth in sales and marketing. The company plans to release AI-powered modules, starting with DermAI in December 2018. Proscia was co-founded in 2014 by CEO David West, CTO Coleman Stavish, chief product officer Nathan Buchbinder, and Hunter Jackson.
May 2017Seed-$900K-
Jul 2016SeedEmerald Development Managers (lead); TCP Venture Capital; A-Level Capital; Robin Hood Ventures$2M-

Who has invested in Proscia?

18 investors have backed Proscia across its funding rounds, including Robin Hood Ventures, Emerald Development Managers, Razor's Edge Ventures, Flybridge, Scale Venture Partners and Fusion Fund.

Lead investors include Alpha Intelligence Capital, Insight Partners, Triangle Peak Partners, Scale Venture Partners, Flybridge and 2 other investors.


Proscia Investors

Investors in Proscia by funding rounds participated
InvestorHQRoundsRoleFirst check
Robin Hood VenturesUnited StatesPhiladelphia, PA5ParticipantJul 2016
Emerald Development ManagersUnited StatesNew York City, NY5LeadJul 2016
Razor's Edge VenturesUnited StatesReston, VA4ParticipantSep 2018
Scale Venture PartnersUnited StatesSan Francisco, CA3LeadNov 2020
Triangle Peak PartnersUnited StatesSan Francisco, CA3LeadJun 2022
FlybridgeUnited StatesNew York City, NY3LeadSep 2018
Hitachi VenturesGermanyMunich3ParticipantNov 2020
Fusion FundUnited StatesSan Francisco, CA3ParticipantSep 2018
Alpha Intelligence CapitalLuxembourgLuxembourg3LeadJun 2022
ROBO GlobalUnited StatesDallas, TX2ParticipantJun 2022
Highline Capital ManagementUnited StatesNew York City, NY2ParticipantJun 2022
SoGal VenturesUnited StatesNew York City, NY1LeadSep 2018
GPG HealthcareUnited StatesBoston, MA1ParticipantMar 2025

This data is available for Pro users. Sign up to see all 18 Proscia investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Proscia Competitors

Proscia competitors include listed companies like GE HealthCare, Pro Medicus, United Imaging and RaySearch Labs, and private ones like United Imaging Intelligence and Viz.

Public and private companies comparable to Proscia
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
GE HealthCareUnited StatesUnited StatesPublicly listed$21B$3.7B$29B1.8x
Pro MedicusAustraliaAustraliaPublicly listed$186M$147M$13B62.7x
United ImagingChinaChinaPublicly listed$2.1B$367M$12B4.8x
United Imaging IntelligenceChinaShanghaiPrivate--$1.4B-
VizUnited StatesUnited StatesPrivate$100M-$1.3B12.8x
RaySearch LabsSwedenSwedenPublicly listed$137M$59M$583M4.2x

Proscia Public Comps

Proscia is still privately-owned, but its public comps include Natera, IQVIA, Agilent, Veeva, IDEXX Laboratories, Roper Technologies, GE HealthCare, Quest Diagnostics, Labcorp and Guardant Health.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Natera$2.3B($266M)22.5x19.0x(195.0x)(261.5x)
IQVIA$16B$3.4B3.6x3.4x17.2x14.8x
Agilent$6.9B$1.8B6.7x6.2x26.1x21.0x
Veeva$3.2B$965M11.1x10.2x36.9x22.4x
IDEXX Laboratories$4.3B$1.5B9.5x8.9x27.1x24.9x
Roper Technologies$7.9B$3.2B6.1x5.7x15.2x14.6x
GE HealthCare$21B$3.7B1.8x1.8x10.1x10.0x
Quest Diagnostics$11B$2.2B3.0x2.9x15.5x14.5x

This data is available for Pro users. Sign up to see all Proscia competitors and their valuation data.

Start Free Trial

Common questions about Proscia

When was Proscia founded?Proscia was founded in 2014.
Where is Proscia headquartered?Proscia is headquartered in Philadelphia, PA, United States.
Is Proscia publicly listed?No, Proscia is a private, VC-backed company.
How much funding has Proscia raised?Proscia has raised $130M across 7 funding rounds.
What was Proscia's last funding round?Proscia's last funding round was a $50M Series D in March 2025, led by Alpha Intelligence Capital, Insight Partners and Triangle Peak Partners.
Who are Proscia's investors?Proscia's investors include Robin Hood Ventures, Emerald Development Managers, Razor's Edge Ventures, Scale Venture Partners, Triangle Peak Partners, Flybridge, Hitachi Ventures, Fusion Fund, Alpha Intelligence Capital, ROBO Global and 8 others.
Which companies are comparable to Proscia?Companies comparable to Proscia include GE HealthCare, Pro Medicus, United Imaging, United Imaging Intelligence, Viz and RaySearch Labs.

See companies similar to Proscia

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial